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IFNλ Stimulates MxA Production in Human
Dermal Fibroblasts via a MAPK-Dependent
STAT1-Independent Mechanism
Adewonuola A. Alase1, Yasser M. El-Sherbiny2,3, Edward M. Vital2, Desmond J. Tobin1, Neil A. Turner4 and
Miriam Wittmann1,2,5,6
IFNλ is important for epidermal defense against viruses. It is produced by, and acts on, keratinocytes, whereas
ﬁbroblasts were previously considered to be unresponsive to this type III IFN. Herein we report ﬁndings
revealing cell type-speciﬁc differences in IFNλ signaling and function in skin resident cells. In dermal ﬁbroblasts,
IFNλ induced the expression of myxovirus protein A (MxA), a potent antiviral factor, but not other IFN signature
genes as it does in primary keratinocytes. In contrast to its effect on keratinocytes, IFNλ did not phosphorylate
signal transducer and activator of transcription 1 in ﬁbroblasts, but instead activated mitogen activated protein
kinases (MAPK). Accordingly, inhibition of MAPK activation (p38 and p42/44) blocked the expression of MxA
protein in ﬁbroblasts but not in keratinocytes. Functionally, IFNλ inhibited proliferation in keratinocytes but not
in ﬁbroblasts. Moreover, IFNλ upregulated the expression of Tumor growth factor beta 1 (TGFβ1)-induced
collagens in ﬁbroblasts. Taken together, our ﬁndings identify primary human dermal ﬁbroblasts as responder
cells to IFNλ. Our study shows cutaneous cell type-speciﬁc IFN signaling and suggests that IFNλ, although
important for epidermal antiviral competence, may also have a regulatory role in the dermal compartment
balancing type I IFN-induced inhibition of tissue repair processes.
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INTRODUCTION
Fibroblasts and keratinocytes are the main tissue cell types
found in the dermis and epidermis respectively. Although
many recent studies have identiﬁed the immunological role of
keratinocytes, the role of dermal ﬁbroblasts in host defense
and inﬂammatory diseases is only beginning to emerge.
Furthermore, dermal ﬁbroblasts synthesize extracellular
matrix including collagens (Xu et al., 2009) and thus have
an important role in maintaining skin structure and wound
healing. IFNλ is a type III IFN comprising four members,
IFNλ1 (IL-29), IFNλ2 (IL-28A), IFNλ3 (IL-28B), and IFNλ4
(Kotenko et al., 2003; Sheppard et al., 2003; Prokunina-
Olsson et al., 2013). IFNλ belongs to the IL-10 family of
cytokines along with IL-10, IL-19, IL-20, IL-22, IL-24, and
IL-26. IFNλ uses the heterologous receptor complex compris-
ing IFNλR1 (also known as IL-28Rα1) and the ubiquitously
expressed IL-10 receptor 2 (IL-10Rβ) which is also used by
IL-10, IL-22, and IL-26 as a second receptor subunit (Kotenko
et al., 2003; Sheppard et al., 2003). IFNλR1 is the signaling
subunit and so its presence determines cellular
responsiveness. Although IFNλ is structurally related to
IL-10, it resembles type I IFNs in its antiviral and
antiproliferative functions (Miknis et al., 2010). They both
signal mainly through the recruitment and activation of
members of the Janus family of kinases, JAK1/TYK2 leading
to the phosphorylation of signal transducer and activator of
transcription (STAT) 1/2 and subsequently to induction of a set
of downstream genes known as IFN-stimulated genes (ISGs)
coding for proteins, such as Myxovirus protein A (MxA),
Guanylate binding protein 1 (GBP-1), 2,5-oligoadenylate
synthetase (2,5-OAS), and IFN inducible protein 16 (IFI-16)
with potent antiviral activities (Ank et al., 2008; Sommereyns
et al., 2008). Beyond JAK/STAT activation, type I IFNs have
also been found to activate mitogen activated protein kinase
(MAPK; p38 and Extracellular signal-regulated kinases ERK
(p42/p44) MAPK), which allows for full activation of
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downstream ISGs (Nguyen et al., 2000; Uddin et al., 2000);
and possibly downstream phosphorylation of STAT1 on serine
727 (Goh et al., 1999).
Type I IFNs signal through membrane associated IFNAR1
and IFNAR2 (Lutfalla et al., 1995). Different from the two
subunits of IFNAR which are present on all nucleated cell
types, IFNλR1 is selectively expressed and functional in
certain cell types only (Kotenko et al., 2003; Witte et al.,
2009; Zahn et al., 2010; Dickensheets et al., 2013). Witte
et al. (2009) described the presence of IL-28Rα1 mRNA
expression in human dermal ﬁbroblasts. However, it was
observed that these cells were unresponsive to IFNλ, and this
was attributed to the very low expression level of the receptor
in these cells (Lasfar et al., 2011).
IFNλ is the main IFN produced by keratinocytes and
production of varying amounts of this cytokine has been
reported also in other cell types (Zahn et al., 2010; Yin et al.,
2012; Wolk et al., 2013). Keratinocytes are susceptible to
IFNλ1 and this cytokine substantially contributes to the
antiviral competence of the human epidermis (Wolk et al.,
2013). Apart from antiviral properties, both types I and III IFNs
are known for their proapoptotic and antiproliferative
activities (Maher et al., 2008; Abushahba et al., 2010; Steen
and Gamero, 2010). These activities have been linked to the
ability of IFNs to phosphorylate STAT1 (Zitzmann et al.,
2006). High expression of ISGs, such as CXCL9, CXCL10,
MxA, and GBP-1 has been reported in interface dermatitis
conditions including cutaneous lupus erythematosus (CLE)
and here increased expression is linked with disease severity
(Wenzel et al., 2005; Naschberger et al., 2010).
In this study, we sought to understand if human dermal
ﬁbroblasts are responsive to IFNλ1 through the activation of
STAT1 and subsequent downstream induction of ISGs. We
also wanted to understand the role of this cytokine in
maintenance of skin integrity with regard to collagen
expression and proliferation of skin resident cells.
RESULTS
IFNλR1 is expressed by human dermal ﬁbroblasts
To conﬁrm the expression of IFNλR1 in ﬁbroblasts and to
investigate its regulation, ﬁbroblasts were stimulated for 4 or
16 hours for analysis of mRNA and protein expression,
respectively. mRNA expression was measured by quantitative
real time polymerase chain reaction (qRT-PCR) and protein
expression was measured by western blotting and ﬂow
cytometry. We found that IFNλR1 was expressed in dermal
ﬁbroblasts and was upregulated in the presence of IFNα
(Figure 1a–e and Supplementary Figure S1 online).
IFNλ induces signiﬁcant expression of MxA in human dermal
ﬁbroblasts
To investigate if IFNλR1 is functional in human dermal
ﬁbroblasts, cells were treated with rhIFNλ or rhIFNα (positive
control) for 4 or 24 hours. mRNA expression of ISGs was
quantiﬁed using qRT–PCR. We found signiﬁcant expression of
MxA but not GBP-1 (Figure 2), OAS2 (Supplementary Figure
S2 online) or other analyzed ISGs (CXCL9 and IFI-16; not
shown) after 4 and 24 hours of IFNλ1 treatment. As expected,
when compared with IFNλ1, IFNα induced signiﬁcantly
higher expression of MxA and GBP-1 after 4 hours of
treatment (Figure 2a–d). However, while the expression of
MxA remained high after 24 hours of treatment with IFNα,
GBP-1 expression dropped signiﬁcantly over this time period
(Figure 2). In ﬁbroblasts, IFNα appeared to induce higher
upregulation of MxA as compared with GBP-1 (Figure 2). IFNλ1
was shown to have a dose-dependent effect on MxA expression
in dermal ﬁbroblasts (Supplementary Figure S3 online).
IFNα and IFNλ induce ISGs expression in human primary
keratinocytes
We compared our ﬁndings on ISGs expression in ﬁbroblasts
with the expression pattern in human primary keratinocytes.
The responsiveness of keratinocytes to both type I and III IFNs
is well documented (Zahn et al., 2010, 2011; Bachmann
et al., 2013). We found that both IFNα and IFNλ1 induced
signiﬁcant mRNA expression of MxA, OAS2, and GBP-1 with
a higher induction of MxA as compared with OAS2 and
GBP-1 (Figure 2 and Supplementary Figure S2 online).
Interestingly, we observed a different time kinetic for the
ISG response to IFNα as compared with IFNλ1. IFNα showed
a strong upregulation of MxA and GBP-1 at 6 hours, whereas
IFNλ1 stimulation resulted in a strong increase in MxA and
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Figure 1. IFNλR1 expression and production in human dermal ﬁbroblasts.
Cultured dermal ﬁbroblasts were either untreated or treated with 10 ngml−1
IFNα for 4 or 16 hours in serum-free Dulbecco's Modiﬁed Eagle's medium
(DMEM) for mRNA and protein expression, respectively. mRNA expression
was measured using qRT-PCR and protein by western blotting and ﬂow
cytometry. (a) qPCR products for IFNλR1 and housekeeping gene U6snRNA
on 2% agarose gel are shown as a representative of ﬁve independent
experiments. (b) Relative mRNA expression. (c) A representative western blot
result for IFNλR1 protein and (d) protein band intensity analysis are depicted;
n= 3. (e) A representative (n=3) histogram of ﬂow cytometric analysis of
IFNλR1 and appropriate isotype control. For statistical analysis, Mann–
Whitney U test was used. Values represent mean± SEM. **Po0.01.
K, keratinocytes; UT, untreated.
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GBP-1 expression after 24 hours. This suggests that IFNλ1
stimulation may result in more delayed and/or longer lasting
effects (Figure 2) as previously observed in hepatocytes (Bolen
et al., 2014).
IFNλ activates p38 and ERK MAPKs but not STAT1 (Tyr701) in
human dermal ﬁbroblasts
Having established that dermal ﬁbroblasts respond to IFNλ1,
we were interested in understanding the mechanism of
action. To achieve this, dermal ﬁbroblasts were treated with
either IFNλ1 or IFNα for different time periods and protein
phosphorylation was determined using western blotting.
As expected, IFNα-induced STAT1 phosphorylation with
maximal phosphorylation detected after 30minutes of stimu-
lation (Figure 3a). However, we failed to observe any STAT1
phosphorylation in IFNλ1-treated cells in any of the time
points investigated. Published studies have reported that
phosphorylation of p38 may be necessary for full activation of
STAT1-dependent genes (Goh et al., 1999; Uddin et al., 2000;
Platanias, 2003). We therefore investigated the ability of
IFNλ1 to induce the phosphorylation of p38 in dermal
ﬁbroblasts and clearly found activation of this MAPK
(Figure 3a). We conﬁrmed that IFNα treatment resulted in
p38 phosphorylation in addition to STAT1 phosphorylation
(Figure 3a). Furthermore, we found that both IFNα and IFNλ1
induced phosphorylation of ERK (Figure 3a), but not the Akt
(p60; data not shown) pathway in dermal ﬁbroblasts. As
expected, we found that both IFNα and IFNλ1 induced STAT1
phosphorylation in primary keratinocytes (Figure 3b).
However, we failed to observe clear activation of either the
p38 or ERK pathway upon treatment with IFNs (Figure 3b).
P38 and ERK inhibitors attenuate IFNλ1-induced MxA protein
expression
We sought to understand if the activation of p38 and ERK was
responsible for the induction of MxA expression in dermal
ﬁbroblasts. To investigate this, ﬁbroblasts were pretreated with
p38 (10 μM SB203580) or ERK (30 μM PD98059 or 10 μM
U0126) inhibitors for 1 hour before treatment with IFNλ1 or
IFNα. mRNA and protein expression levels were measured by
qRT–PCR and western blotting, respectively. Interestingly, our
results showed that the expression of MxA was not regulated
at the mRNA level by the MAPK inhibitors (Figure 4a and b).
However, the presence of either the p38 or ERK inhibitor
abrogated IFNλ1-induced MxA protein production
(Figure 4c). We did not observe a decrease in IFNα-induced
MxA protein production in ﬁbroblasts in the presence of
SB203580, PD98059 (not shown), or U0126 (Figure 4d). We
also analyzed whether MAPKs had a role in IFNλ1-induced
MxA protein expression in human primary keratinocytes. We
failed to ﬁnd a signiﬁcant effect of p38 or ERK inhibition on
IFNλ1 and IFNα-induced MxA protein production in kerati-
nocytes (Figure 4e).
IFNλ enhances collagen expression in human dermal ﬁbroblasts
As conditions with high type I IFN expression can be linked to
impaired healing responses, we investigated whether IFNλ1
had any inﬂuence on collagen expression. Fibroblasts were
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Figure 2. Interferon stimulated genes (ISGs) expression in human skin resident cells. Cultured dermal ﬁbroblasts were either untreated or treated with
10 ngml−1 IFNα or 100 ngml−1 IFNλ1 for 4 or 24 hours in serum-free medium. Primary keratinocytes were treated with the same concentration of cytokines for
6 or 24 hours in KGM (− /− ). mRNA expression of ISGs was measured using qRT–PCR. Top panel shows expression levels of MxA, 4 hours; MxA, 24 hours;
GBP-1, 4 hours, and GBP-1, 24 hours in ﬁbroblasts. Bottom panel shows expression levels of MxA, 6 hours; MxA, 24 hours; GBP-1, 6 hours, and GBP-1, 24 hours
in keratinocytes. For statistical analysis, Mann–Whitney U test was used; n= 5, values represent mean± SEM. *Po0.05, **Po0.01. GBP, guanulate binding
protein; KGM, keratinocyte growth medium; MxA, myxovirus protein A; UT, untreated.
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treated with IFNλ1, IFNα, TGFβ1, or a combination of IFN and
TGFβ1 for 6 or 24 hours. TGFβ1 was used as a control, given
its well described stimulation of ﬁbroblast proliferation and
collagen synthesis. We measured Col1A1, Col3A1, Col4A2,
and Col7A1 using qRT–PCR. There was no difference in
collagen expression after 6 hours of stimulation with these
cytokines (data not shown). However, after 24 hours of
treatment, TGFβ1 signiﬁcantly induced the collagen expres-
sion. Combined treatment of cells with IFNλ1 and TGFβ1
resulted in a signiﬁcantly higher collagen expression (except
for Col3A1) than with either treatment alone (Figure 5a–d).
To investigate which of the MAPK pathways may be
responsible for the synergy, we treated cultured dermal
ﬁbroblasts with either IFNλ1 or TGFβ1 or both together for
30minutes and analyzed the phosphorylation of p38 and ERK
by western blotting. We found that both IFNλ1 and TGFβ1
activated the p38 and ERK pathways independently
(Supplementary Figure S4 online). Interestingly, we observed
a clear synergistic effect between IFNλ1 and TGFβ1 on the
activation of the p38 pathway. The effect is not very clear
with the ERK pathway (Supplementary Figure S4 online). This
suggests that the p38 pathway may be responsible for the
synergistic effect observed on collagen expression.
IFNλ has potent antiproliferative activity in primary
keratinocytes but not in dermal ﬁbroblasts
The antiproliferative effect of IFNλ1 on HaCaT keratinocyte
cell lines has been described (Maher et al., 2008). We aimed
to compare the effect of both IFNλ1 and IFNα on primary skin
cells. Keratinocytes and ﬁbroblasts were stained with cell
tracer dye and subsequently stimulated with either IFNλ or
IFNα for 72 hours. As expected, both IFNs clearly reduced
keratinocyte proliferation (Figure 6a and b). In contrast, we
observed that IFNα but not IFNλ1 inhibited dermal ﬁbroblast
proliferation (Figure 6c and d). TGFβ1, known to induce
ﬁbroblast proliferation, was used as positive control (Figure 6c
and d).
We also investigated the effects of IFNλ1 and IFNα on
“gap” closure in monolayer cultures of dermal ﬁbroblasts.
We observed the trend that IFNλ1 enhanced gap closure
in ﬁbroblasts while IFNα delayed gap closure after 48 hours
of stimulation in comparison with the untreated cells
(Supplementary Figure S5 online).
DISCUSSION
Type I and III innate IFNs were initially identiﬁed for their potent
antiviral activities (Sadler and Williams, 2008; MacMicking,
2012). In addition, IFNs also have immunoregulatory, anti-
proliferative, and proapoptotic properties; they have been
identiﬁed as potential anticancer drugs (Abushahba et al.,
2010; Witte et al., 2010). However, they are also important
mediators in the pathogenesis of autoimmune diseases, such as
CLE (Meyer, 2009; Ronnblom and Eloranta, 2013). MxA is a
highly inducible ISG and one of the most potent antiviral factors
capable of blocking early replication events of different RNA
and DNA viruses (Sadler and Williams, 2008).
Type III IFN is the most recently described group of IFNs.
Expression of their speciﬁc receptor was thought to be
restricted mainly to epithelial cells (keratinocytes) and
hepatocytes. There is, however, emerging evidence that
IFNλR1 is also present and functional on hematopoietic cells
(Mennechet and Uze, 2006; Dai et al., 2009; Liu et al., 2011;
Yin et al., 2012). There are reports identifying MAPKs as
regulators of IFN downstream activities (Uddin et al., 2000;
van Boxel-Dezaire et al., 2006; Gough et al., 2008) and the
importance of different (non JAK) kinases activated in
response to IFNs has been speculated before to contribute
to cell-type and IFN subtype speciﬁc responses (van Boxel-
Dezaire et al., 2006). Our work shows a distinct signaling and
also functional response of primary human ﬁbroblasts to IFNλ,
which is different from the response of these cells to type I IFN
and clearly different from the response of epidermal cells.
Indeed, keratinocytes show a similar signaling and functional
response to both type I and type III IFNs which is charac-
terized by a STAT1-dependent upregulation of a broad range
of ISGs. Dermal ﬁbroblasts were considered unresponsive
to IFNλ (Abushahba et al., 2010). We here show that human
ﬁbroblasts indeed respond to IFNλ1 treatment with signiﬁcant
expression of MxA mRNA and protein. In line with our
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Figure 3. IFNλ1 induced mitogen activated protein kinase (MAPK) and signal
transducer and activator of transcription 1 (STAT1) phosphorylation in
ﬁbroblasts and keratinocytes, respectively. Cultured human dermal
ﬁbroblasts (a) or primary keratinocytes (b) were either non-treated or treated
with 10 ngml−1 IFNα or 100 ngml−1 IFNλ1 for 10, 30, or 60 minutes,
respectively. Total and phosphorylated p38, ERK, and STAT1 along with
GAPDH were detected by western blot. A representative out of three
independent experiments is depicted. ERK, extracellular signal–regulated
kinase; UT, untreated.
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ﬁndings, a recent study has reported the responsiveness of
cytomegalovirus infected foreskin ﬁbroblast to IFNλ3 (Egli
et al., 2014). It is well documented that type I and III IFNs
induce similar sets of ISGs in many cell types (Ank et al.,
2008; Sommereyns et al., 2008). However, in ﬁbroblasts, we
failed to observe signiﬁcant expression of GBP-1, OAS2, or
other ISGs upon IFNλ1 treatment. The inability of IFNλ1 to
activate STAT1 (Tyr701) in ﬁbroblasts was unexpected as this
R
el
at
iv
e 
m
R
N
A 
ex
pr
es
sio
n
MxA 4 h
MxA
MxA
MxA 24 h
600
400 400
200 200
20 20
10 10
0 0
Un
tre
ate
d
DM
SO SB SBU U
IFN
λ1
IFNλ1
IFNλ1
IFNλ1
SB
+IF
Nλ
1
U+
IFN
λ1
IFN
α
IFNα
IFNα
SB
+IF
Nα
SB+IFNα
U+
IFN
α
U+IFNα
Un
tre
ate
d
DM
SO
IFN
λ1
SB
+IF
Nλ
1
SB+IFNλ1
U+
IFN
λ1
U+IFNλ1
IFN
α
SB
+IF
Nα
U+
IFN
α
IFN
λ1
SB
+IF
Nλ
1
U+
IFN
λ1
SB
+IF
Nα
U+
IFN
α
DMSO
DMSO
DMSO
GAPDH
GAPDH
SB
SB
U
U
MxA
IFNα
IFN
α
GAPDH
SB
U
Fibroblasts
Fibroblasts
100
80
60
40
20
0
100
80
60
40
20
0
100
80
60
40
20
0
%
 P
ro
tie
n 
ba
nd
 in
te
ns
ity
M
xA
/G
AP
DH
%
 p
ro
tie
n 
ba
nd
 in
te
ns
ity
M
xA
/G
AP
DH
%
 P
ro
tie
n 
ba
nd
 in
te
ns
ity
M
xA
/G
AP
DH
+
+
+ +
+
+
+
– – –
– –
–
–
––
–
–
+
+
+ +
+
+
+
+
+++
+ +
– – –
– –
–
–
––
–
–
+ + +
+ + +– – – – –
– – –
–
– – – – – –
– –
– – – – –
–
–
Keratinocytes
a b
c
d
e
* *
Figure 4. Inhibition of myxovirus protein A (MxA) production by p38 and extracellular signal–regulated kinase (ERK) inhibitors. Cultured dermal ﬁbroblasts or
primary keratinocytes were either untreated or treated with MAPK inhibitors or IFNs for 4 and 24 hours and MxA was detected on the mRNA level and by western
blot (24 hours). (a) MxA mRNA expression, 4 hours; n=3; (b) MxA mRNA expression, 24 hours; n=3; (c) MxA protein expression by IFNλ1 in the presence or
absence of MAPK inhibitors in ﬁbroblasts; (d) MxA protein expression by IFNα in the presence or absence of MAPK inhibitors in ﬁbroblasts; (e) MxA protein
expression by IFNλ1 and IFNα in human primary keratinocytes in the presence or absence of MAPK inhibitors. Figures are representative of three independent
experiments. For statistical analysis, unpaired t test was used; values represent mean± SEM. *po0.05. SB: SB203580 (p38 inhibitor); U: U0126 (MEK/ERK
inhibitors). MAPK, mitogen activated protein kinase.
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is the known canonical pathway for the induction of
downstream ISG genes. However, our ﬁndings on IFNλ1-
induced activation of both p38 and ERK suggest that the
MAPK pathway may be an alternative for the induction of
MxA by IFNλ in ﬁbroblasts. It has been suggested that
IFNα-induced phosphorylation of MAPKs and STAT1 are
independent of each other; however, they work in tandem to
ensure full activation of ISGs (Li et al., 2004). It is interesting
that the inhibition of p38 and ERK in IFNα-treated dermal
ﬁbroblasts did not result in signiﬁcant downregulation of MxA
protein expression; although we observed a slight reduction in
MxA production by primary keratinocytes following inhibition
of ERK but not p38. Activation of PI3K-AKT and Raf-MEK-ERK
pathways by IFNλ1 and IFNα in HepG2.2.15 cell lines has
been reported (Chai et al., 2011), but we could not observe
AKT pathway activation in our experiments. Our proposed
mechanism of IFNα and IFNλ1 signaling in dermal ﬁbroblasts
is shown in Supplementary Figure S6 online. To our surprise,
we failed to observe any signiﬁcant regulatory effects of the
MAPK inhibitors at the transcriptional level suggesting that
p38 and ERK inhibition results in posttransciptional regulation
of MxA. Mechanisms of mRNA translation of ISGs have
recently been reviewed (Joshi et al., 2010). Both the p38 and
p42/44 MAPKs can control the activation of eIF4E and other
substrates of MAPK interacting protein kinases 1 and 2 (Mnk1
and 2) which inﬂuence translation initiation (Joshi et al.,
2010). Posttransriptional regulation of TNFα gene expression
in the presence of p38 inhibitor has been described (Clark
et al., 2003). Future experiments will need to further dissect
the underlying events of the posttranscriptional regulation
observed for MxA in dermal ﬁbroblasts. In this study, we have
conﬁrmed previous report that human dermal ﬁbroblasts
express IFNλR1 (Witte et al., 2009) and that IFNα can
upregulate its expression. The ability of IFNα to enhance the
expression levels of IFNλR1 is evidence of a cross-talk
between type I and type III IFNs (Duong et al., 2014).
TGFβ1 is well known to induce collagen expression in
ﬁbroblasts. Types I, III, IV, and VII collagens are the main
components of extracellular matrix (ECM), basement mem-
brane zone, and the anchoring ﬁbrils at the dermal–epidermal
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Figure 5. Effect of IFNλ on collagen expression in human dermal ﬁbroblasts.
Cultured dermal ﬁbroblasts were either untreated or treated with 10 ngml−1
IFNα, 100 ngml−1 IFNλ1, 5 ng ml−1 TGFβ1 or combination of IFNλ1 and
TGFβ1 for 24 hours. mRNA expression of ISGs was measured using qRT–PCR.
Depicted is Col1A1 (a), Col3A1 (b), Col4A2 (c), and Col7A1 (d) expression. For
statistical analysis, Mann–Whitney U test was used; n=5, values represent
mean± SEM. *Po0.05, **Po0.01. ISG, Interferon stimulated gene.
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Figure 6. Effects of IFNs on proliferation of skin resident cells. Dermal
ﬁbroblasts or primary keratinocytes were labeled with cell trace violet in
DMEM containing 1% fetal bovine serum and keratinocyte growth medium,
respectively. Daughter cell populations (highlighted by different colors) of
dividing cells were visualized by ﬂow cytometry after 72 hours of stimulation.
Increased proliferation results in a shift to the left end of the histogram.
(a) Fluorescent signal in keratinocytes at day 0 and after exposure to IFNλ1/
IFNα/medium for 72 hours. (b) Percentage proliferation of keratinocytes
(n=3). (c) Percentage proliferation of ﬁbroblasts (n= 3). (d) Fluorescent signal
in ﬁbroblasts at day 0 and 72 hours after stimulation with TGFβ/IFNλ1/IFNα/
medium. For statistical analysis, unpaired t-test was used; n=3, values
represent mean± SEM. **Po0.01. UT, untreated.
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junction (Heino, 2007). We found that IFNλ1 potentiated the
TGFβ-associated induction of collagen I, IV, and VII most
probably by synergistic effect with TGFβ1 on p38 activation.
This effect was not observed for collagen type III expression.
IFNγ, a type II IFN exhibited an inhibitory effect on TGFβ1-
induced ECM or collagen deposition in primary human lung
(Eickelberg et al., 2001) and in human foreskin ﬁbroblasts
(Ghosh et al., 2001). Of interest, keloid-derived dermal
ﬁbroblasts seem non-responsive to this IFNγ-dependent type
I collagen regulation (Hasegawa et al., 2003). Excessive
secretion of type I collagen is linked with hypertrophic scar
formation, whereas a sufﬁcient amount of type III collagen
may prevent scar formation (Oliveira et al., 2009). The net
effect of IFNλ1 on cutaneous repair and healing responses is
not clear yet and needs to be further investigated. The ability
of IFNλ1 to upregulate the expression of type IV (Col4A2) and
VII collagens (Col7A1) suggests that it may support basement
membrane integrity (Nystrom et al., 2013).
Our results on proliferation of primary keratinocytes are
consistent with the roles of IFNα and IFNλ1 as antiprolifera-
tive agents. However, we show that IFNλ1 does not have an
inhibitory effect on dermal ﬁbroblasts’ proliferation and this
may be due to its inability to induce STAT1 phosphorylation
in these cells. In addition, the antiproliferative ability of GBP-1
on intestinal epithelial cells has been described (Capaldo
et al., 2012) and IFNλ1 failed to induce GBP-1 expression in
dermal ﬁbroblasts.
In summary, this study has shown that IFNλR1 is active in
dermal ﬁbroblasts through the activation of p38 and ERK
pathways. We have shown that MxA induction by IFNλ1
occurs through a STAT1-independent pathway and this may
also explain the role of this cytokine in enhancement of
collagen expression and lack of antiproliferative activity. We
suggest that the physiologic role of IFNλ activity in the skin
organ is certainly linked with viral defense. Keratinocytes as
outer barrier cells are main producers of IFNλ. An infection
beyond the epidermal compartment will lead to increased
expression of antiviral type I IFNs which in turn increase the
susceptibility of ﬁbroblasts to epidermal type III IFNs. Dermal
ﬁbroblasts will contribute to the antiviral competence of the
skin tissue by upregulation of MxA protein. In the context of
damage caused by a viral infection, they may however have
an important part in maintaining tissue integrity and allowing
repair processes involving basement membrane and type I
collagens; as well as mesenchymal cell proliferation. This
“repair” phenotype may manifest with some delay in the
inﬂammatory antiviral response once the more potent, but
shorter signaling effect of type I IFNs decreases. This
suggested “regulatory” role of type III IFNs on dermal tissue
cells is supported by ﬁndings from Egli et al. (2014) who
described that in cytomegalovirus-treated foreskin derived
ﬁbroblast cell lines, IFNλ exerts an inhibitory action on IFNα-
induced activity. We propose that the dermal response to
IFNλ1 could counteract type I IFN-induced impairment of
repair mechanisms. With regard to CLE where IFNλ is highly
expressed, our current data do not support a prominent role
of IFNλ in repair failure and antiproliferative activity seen
in discoid CLE (Nyberg et al., 2000). However, further
experiments regarding functional analysis of skin lesion-
derived cells would be necessary to verify this assumption.
MATERIALS AND METHODS
Cytokine and antibodies
Recombinant human (rh) IFNλ1 (100 ngml− 1) was purchased from
ebioscience (Hatﬁeld, UK); rhIFNα2a (10 ngml− 1; Merck Millipore,
Merck Serono, Middlesex, UK), rhTGFβ1 (5 ng ml−1; Peprotech EC,
London, UK). Anti-human (rabbit phospho p38, mouse phospho ERK,
mouse ERK, rabbit p38, rabbit phospho STAT1, and rabbit
STAT1) antibodies were purchased from Cell signaling Technology
(Leiden, The Netherlands); anti-human (rabbit MxA, rabbit
IFNλR1, and mouse GAPDH) antibodies were purchased from
Abcam (Cambridge, UK) and Santa Cruz (Insight Biotechnology,
Middlesex, UK), respectively. Horseradish peroxidase (HRP)
conjugated donkey anti-rabbit and donkey anti-mouse secondary
antibodies were from Santa Cruz. PD98059, U0126 (MEK/ERK
inhibitors), and SB203580 (p38 inhibitor) were from Cell Signaling
Technology.
Cell isolation, culture, and ethics
Keratinocytes and dermal ﬁbroblasts were derived from skin tissue
from anonymized healthy volunteers undergoing cosmetic surgery.
Samples were collected following written informed consent by
patients and local research ethical approval (Ethical Tissue,
University of Bradford). Skin samples were processed on the day of
collection. Fibroblasts were isolated by placing the trypsinized
dermis in a T75 culture ﬂask, ensuring the upper layer just below the
epidermis adhered ﬁrmly to the ﬂask. A volume of 10 ml DMEM
containing 10% FBS was carefully added to the ﬂask so as not
to allow the dermis to ﬂoat. Fibroblasts explanted after 5 to 7 days.
Full details are given in Supplementary Information.
Cell stimulation
Keratinocytes or ﬁbroblasts were seeded into 24-well or 6-well plates
and allowed to grow to ≈80% conﬂuency. For keratinocytes, culture
medium was replaced with KGM without human epidermal growth
factor and hydrocortisone (KGM−/−) prior to cell treatment with
cytokines. Dermal ﬁbroblasts were starved of serum for 24 hours
before treatment in serum-free DMEM. For inhibition experiments,
cells were pre-treated for 1 hour with 10 μM SB203580 (Cell
Signaling), 30 μM PD98059 or 10 μM U0126 (Cell Signaling) before
treatment with IFNα or IFNλ1. Controls included untreated cells and
cells treated with DMSO, SB203580, or PD98059/U0126 alone for
24 hours.
Quantitative RT–PCR
Mx1, GBP-1, OAS2, IFI-16, CXCL9, IFNλR1, Col1A1, Col3A1,
Col4A2, and Col7A1 QuantiTect primer assays were obtained from
Qiagen (Hilden, Germany), whereas U6snRNA primer (forward—
5′-CTCGCTTCGGCAGCACA-3′; reverse-5′-AACGCTTCACGAATTT
GC-3′) was purchased from Sigma-Aldrich, Poole, UK. The following
parameters were used: initial heat activation, 95 °C for 5 minutes;
denaturation, 95 °C for 10 seconds; combined annealing and
elongation, 60 °C for 30 seconds for a 40 cycle run. Data
were analyzed using the delta–delta ct method. mRNA expression
of each gene of interest was normalized to U6snRNA
housekeeping gene.
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Agarose gel electrophoresis
qRT-PCR products were run at 40mA for 30minutes on 2% agarose
gel. Image was taken under UV light. Full details are given in
Supplementary Information.
Western blotting
Cells were lysed with CelLytic M lysis buffer (Sigma-Aldrich)
containing protease inhibitor cocktail (Roche Applied Bioscience,
Rotkreuz, Switzerland) and phosphatase inhibitor (Thermo Scientiﬁc,
Loughborough, UK). 30 μg of total protein was separated on any kDa
mini protean gel (Bio-Rad) and proteins were blotted onto 0.2 μm
PVDF trans-blot pack (Bio-Rad, Hemel Hempstead, UK). Membranes
were probed with rabbit anti-human pSTAT1 (1:1000), STAT1
(1:1000), phospho p38 (1:1000), mouse anti-human pERK (1:2000),
p38 (1:1000), or GAPDH (1:3000) in Tris-buffered saline/0.1%
Tween-20 (TBST) containing 5% BSA overnight at 4 °C. Rabbit anti-
human MxA (1:1000), IFNλR1 (1:1000), and GAPDH were used in
5% milk phosphate buffered saline/0.1% Tween-20 (PBST) overnight
at 4 °C. Donkey anti-rabbit and donkey anti-mouse HRP-conjugated
secondary antibodies were used at 1:5000 and 1:3000 respectively
for 1 hour at room temperature. For a repeat Western, membranes
were stripped, blocked, and re-probed with primary antibody.
CellTrace proliferation assay
Human primary keratinocytes and dermal ﬁbroblasts were stained in
keratinocyte growth medium or serum-free DMEM, respectively, with
CellTrace violet (Molecular probes/Life technologies) away from the
source of light (2 μl cell trace to 1 million cells in 1 ml media). Cells
were plated in six-well plates and were either treated with cytokines
or untreated for 72 hours. Some cells were used for the day 0
analysis. For ﬂow cytometric analysis, a BD LSRFortessa (BD
Bioscience, Oxford, UK) machine was used. Cell proliferation was
calculated using ModFit software version 3.2 (Verity Software House,
Topsham, ME). Full details are given in Supplementary Information.
Statistical analysis
Statistical signiﬁcance was determined using Mann–Whitney test or
unpaired t-test. Analysis was performed using GraphPad Prism
software (GraphPad Software La Jolla, CA). All data are expressed
as means± SEM and values of Po0.05 were considered signiﬁcant.
‘n’ represents independent experiments; *Po0.05, **Po0.01.
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